Showing 6501-6510 of 8783 results for "".
- New Analysis Provides Reassurance on Biosimilar Safetyhttps://practicaldermatology.com/news/new-analysis-provides-reassurance-on-biosimilar-safety/2457964/And they’re … safe. Biosimilars, which have been available in the European Union since 2006, show no substantial differences in the reporting of safety information than their originators, according to a new analysis in the
- Meet the ASDSA 2017 State Patient Safety Hero Award Honoreeshttps://practicaldermatology.com/news/meet-the-asdsa-2017-state-patient-safety-hero-award-honorees/2458020/The American Society for Dermatologic Surgery Association (ASDSA) honored the recipient
- Review Study Suggests Vitamin B3 May Prevent Melanomahttps://practicaldermatology.com/news/review-study-suggests-vitamin-b3-may-prevent-melanoma/2458093/Nicotinamide (Vitamin B3) may help stave off melanoma in high-risk individuals, a new review study suggests. “Nicotinamide has been shown in a clinical trial—called ONTRAC—to reduce the incidence of non-melanoma skin cancer in high-risk individuals and it would be worthw
- Research on Nitric Oxide-Releasing Nanoparticles Reveals Promising Skin Infection Treatmenthttps://practicaldermatology.com/news/research-on-nitric-oxide-releasing-nanoparticles-reveals-promising-skin-infection-treatment/2458095/George Washington University (GW) researchers have found that topically applied nitric oxide-releasing nanoparticles (NO-np) are a viable treatment for deep fungal infections of the skin caused by dermatophyt
- La Roche-Posay Supports Oncodermatology Clinic at George Washington Universityhttps://practicaldermatology.com/news/la-roche-posay-supports-oncodermatology-clinic-at-george-washington-university/2458196/
- Allergan Officially Adds Coolsculpting to Portfoliohttps://practicaldermatology.com/news/allergan-adds-coolsculpting-to-portfolio/2458207/It’s a done deal. Allergan now owns ZELTIQ® Aesthetics. Allergan acquired ZELTIQ® Aesthetics for approximately $2.4 billion in cash. ZELTIQ® stockholders approved the transaction during its stockholder meeting h
- Topline Results from Novan's SB204 Phase 3 Pivotal Trials: Inconsistent Across Trialshttps://practicaldermatology.com/news/novan-reports-topline-results-from-sb204-phase-3-pivotal-trials/2458306/Novan, Inc. (NASDAQ:
- Specialty Pharma Industry Vet Charles Gregory Vontz Joins BioPharmX Board of Directorshttps://practicaldermatology.com/news/specialty-pharma-industry-vet-charles-gregory-vontz-joins-biopharmx-board-of-directors/2458311/Charles "Greg" Vontz is joining rhe Board of Directors of BioPharmX Corporation as an independent director, effective as of Jan. 17. Vontz's appointment expands the board to four directors, three of whom are independent.
- Beauty Drinks Poised to Be Cosmeceutical Industry's Next Billion-Dollar Babyhttps://practicaldermatology.com/news/beauty-drinks-poised-to-be-cosmeceutical-industrys-next-billion-dollar-baby/2458361/Beauty drinks are everywhere today, and many youth seekers turning to them as a way to improve skin and get their glow on from the inside out. In fact, beauty drinks are slated to become a billion dollar market, according to a new
- Virtual Peer Pressure on Social Media May Up Indoor Tanning in Young Womenhttps://practicaldermatology.com/news/virtual-peer-pressure-on-social-media-may-up-indoor-tanning-in-young-women/2458523/Use of Twitter and Instagram may be driving an uptick in indoor tanning among young adult women, a new study suggests. The study, which appears in the July issue of the Journal of the American Academ